144 related articles for article (PubMed ID: 38279414)
1. Role of Platelet-Derived Growth Factor-mediated signaling in carcinogenesis and metastasis.
Farooqi AA; Attar R
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):300-302. PubMed ID: 38279414
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.
Farooqi AA; Siddik ZH
Cell Biochem Funct; 2015 Jul; 33(5):257-65. PubMed ID: 26153649
[TBL] [Abstract][Full Text] [Related]
3. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review.
Zou X; Tang XY; Qu ZY; Sun ZW; Ji CF; Li YJ; Guo SD
Int J Biol Macromol; 2022 Mar; 202():539-557. PubMed ID: 35074329
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.
Appiah-Kubi K; Wang Y; Qian H; Wu M; Yao X; Wu Y; Chen Y
Tumour Biol; 2016 Aug; 37(8):10053-66. PubMed ID: 27193823
[TBL] [Abstract][Full Text] [Related]
6. New insights about the PDGF/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies.
Pandey P; Khan F; Upadhyay TK; Seungjoon M; Park MN; Kim B
Biomed Pharmacother; 2023 May; 161():114491. PubMed ID: 37002577
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
8. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
9. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis.
Heldin CH; Lennartsson J; Westermark B
J Intern Med; 2018 Jan; 283(1):16-44. PubMed ID: 28940884
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
11. A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
Ustach CV; Huang W; Conley-LaComb MK; Lin CY; Che M; Abrams J; Kim HR
Cancer Res; 2010 Dec; 70(23):9631-40. PubMed ID: 21098708
[TBL] [Abstract][Full Text] [Related]
12. PDGF-D signaling: a novel target in cancer therapy.
Wang Z; Kong D; Li Y; Sarkar FH
Curr Drug Targets; 2009 Jan; 10(1):38-41. PubMed ID: 19149534
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
Aoki M; Nabeshima K; Koga K; Hamasaki M; Suzumiya J; Tamura K; Iwasaki H
Lab Invest; 2007 Aug; 87(8):767-79. PubMed ID: 17558420
[TBL] [Abstract][Full Text] [Related]
14. PDGFs and their receptors.
Kazlauskas A
Gene; 2017 May; 614():1-7. PubMed ID: 28267575
[TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53.
Yu J; Liu XW; Kim HR
J Biol Chem; 2003 Dec; 278(49):49582-8. PubMed ID: 14506245
[TBL] [Abstract][Full Text] [Related]
16. PDGF BB induces VEGF secretion in ovarian cancer.
Matei D; Kelich S; Cao L; Menning N; Emerson RE; Rao J; Jeng MH; Sledge GW
Cancer Biol Ther; 2007 Dec; 6(12):1951-9. PubMed ID: 18075302
[TBL] [Abstract][Full Text] [Related]
17. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
Rosenberg A; Mathew P
Expert Opin Investig Drugs; 2013 Jun; 22(6):787-94. PubMed ID: 23540855
[TBL] [Abstract][Full Text] [Related]
18. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
Abouantoun TJ; MacDonald TJ
Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Lin LH; Lin JS; Yang CC; Cheng HW; Chang KW; Liu CJ
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235327
[TBL] [Abstract][Full Text] [Related]
20. Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.
Najy AJ; Won JJ; Movilla LS; Kim HR
Mol Cancer Res; 2012 Aug; 10(8):1087-97. PubMed ID: 22689130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
